financetom
Business
financetom
/
Business
/
Chevron agrees Hess CEO will not join board in deal with US regulator, Bloomberg News reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chevron agrees Hess CEO will not join board in deal with US regulator, Bloomberg News reports
Sep 26, 2024 9:54 AM

(Reuters) - U.S. energy major Chevron ( CVX ) has agreed Hess CEO John Hess will not join its board in an agreement with the U.S. Federal Trade Commission to proceed with the $53 billion takeover deal, Bloomberg News reported on Thursday citing people familiar with the matter.

The proposed all-stock acquisition, first announced in October, is one of the biggest in the U.S. oil and gas industry and the latest among a slew of multi-billion dollar deals in the space.

Chevron ( CVX ), Hess and the FTC did not immediately respond to Reuters' requests for comments.

The approval clears one hurdle, but Chevron ( CVX ) still needs to win an arbitration challenge filed by Exxon Mobil over Hess' stake in a Guyana oilfield - a coveted asset in the proposed merger.

Exxon and CNOOC Ltd, partners of Hess in the Guyana joint venture, are challenging the deal by claiming a right of first refusal to any sale of Guyana assets.

Hess owns 30% of Guyana's giant Stabroek block operated by Exxon, which owns 45%. China's CNOOC Ltd holds the remaining 25%. The companies expect to double production to 1.3 million barrels of oil and gas per day by 2027.

(Reporting by Sourasis Bose and Mrinalika Roy in Bengaluru; Editing by Anil D'Silva and Krishna Chandra Eluri)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss
MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss
Aug 7, 2024
10:38 AM EDT, 08/07/2024 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) shares were slightly up in recent Wednesday trading despite posting a wider Q2 net loss from a year earlier. The biotechnology company reported a Q2 loss of $0.39 per share, widening from a loss of $0.23 a year earlier. Analysts polled by Capital IQ expected a loss of...
Wolverine Shares Fall as Company Posts Lower Q2 Adjusted EPS, Revenue
Wolverine Shares Fall as Company Posts Lower Q2 Adjusted EPS, Revenue
Aug 7, 2024
10:37 AM EDT, 08/07/2024 (MT Newswires) -- Wolverine World Wide ( WWW ) shares were down 1.7% in recent Wednesday trading after the company reported Q2 adjusted earnings of $0.15 per diluted share, down from $0.19 a year earlier. Analysts polled by Capital IQ expected $0.11. Total revenue for the quarter ended June 29 was $425.2 million, down from $589.1...
Global Partners Q2 Net Income, Sales Rise
Global Partners Q2 Net Income, Sales Rise
Aug 7, 2024
10:36 AM EDT, 08/07/2024 (MT Newswires) -- Global Partners LP ( GLP ) reported Q2 net income Wednesday of $1.10 per diluted limited partner unit, up from $1.05 a year earlier. An analyst polled by Capital IQ expected $1.50. Sales for the quarter ended June 30 were $4.41 billion, compared with $3.83 billion a year earlier. A lone analyst surveyed...
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises; Shares Lower
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises; Shares Lower
Aug 7, 2024
10:37 AM EDT, 08/07/2024 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) shares were about 1.8% lower in early trading Wednesday after the late-stage biopharmaceutical company narrowed its Q2 loss amid higher revenue. The firm reported a Q2 net loss of $0.41 per diluted share, narrower than a net loss of $0.47 per share a year earlier. Analysts polled by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved